These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36497326)

  • 41. Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer.
    Sun B; Hou Q; Liang Y; Xue S; Yao N; Wei L; Cao X; Li H; Si H; Cao J
    BMC Cancer; 2022 Nov; 22(1):1233. PubMed ID: 36447193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.
    Araki T; Tateishi K; Komatsu M; Sonehara K; Kanda S; Hanaoka M; Koizumi T
    Thorac Cancer; 2022 Apr; 13(7):1006-1013. PubMed ID: 35156310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis.
    Hakozaki T; Nolin-Lapalme A; Kogawa M; Okuma Y; Nakamura S; Moreau-Amaru D; Tamura T; Hosomi Y; Takeyama H; Richard C; Hosokawa M; Routy B
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
    Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Rebuzzi SE; Prelaj A; Friedlaender A; Cortellini A; Addeo A; Genova C; Naqash AR; Auclin E; Mezquita L; Banna GL
    Crit Rev Oncol Hematol; 2022 Nov; 179():103806. PubMed ID: 36087850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors.
    Mahiat C; Bihin B; Duplaquet F; Stanciu Pop C; Dupont M; Vander Borght T; Rondelet B; Vanderick J; André B; Pirard L; Ocak S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
    Al Darazi G; Martin E; Delord JP; Korakis I; Betrian S; Estrabaut M; Poublanc M; Gomez-Roca C; Filleron T
    Int J Cancer; 2021 May; 148(10):2502-2511. PubMed ID: 33231298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
    BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.
    Li X; Lu D; Zhang Z; Zhang Y; Wang J; Hu Y
    J Thorac Dis; 2022 Oct; 14(10):4125-4135. PubMed ID: 36389301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital.
    Auclair J; Sanchez S; Chrusciel J; Hannetel L; Frasca M; Economos G; Habert-Dantigny R; Bruera E; Burucoa B; Ecarnot F; Colombet I; Barbaret C
    Support Care Cancer; 2022 Jun; 30(6):4997-5006. PubMed ID: 35192058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
    Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy.
    Obayashi K; Miki J; Fukuokaya W; Yanagisawa T; Kimura S; Tsuzuki S; Kimura T; Egawa S
    Int J Clin Oncol; 2022 Feb; 27(2):396-402. PubMed ID: 34714458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Ikuta S; Komuta K
    World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.